BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Market Closed 06-18 16:00:00 EDT

0.9674

+0.0198

+2.09%

盘后0.9550

-0.0124-1.28%

19:55 EDT

High1.03	Low0.9210	Vol885.46K
Open0.9900	D1 Closing0.9476	Amplitude11.50%
Mkt Cap11.00M	Tradable Cap8.72M	Total Shares11.37M
T/O865.10K	T/O Rate9.83%	Tradable Shares9.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":0.9674,"timestamp":1781812800000,"preClose":0.9476,"halted":0,"volume":885464,"hourTrading":{"tag":"盘后","latestPrice":0.955,"preClose":0.9674,"latestTime":"19:55 EDT","volume":15901,"amount":15344.1072,"timestamp":1781826957393,"change":-0.0124,"changeRate":-0.012818,"amplitude":0.02946},"delay":0,"changeRate":0.02089489235964546,"floatShares":9010150,"shares":11374700,"eps":-0.946888,"marketStatus":"Market Closed","change":0.0198,"latestTime":"06-18 16:00:00 EDT","open":0.99,"high":1.03,"low":0.921,"amount":865099.3905568001,"amplitude":0.115027,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.946888,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.9476,"preHourTrading":{"tag":"盘前","latestPrice":0.97,"preClose":0.9476,"latestTime":"09:17 EDT","volume":17822,"amount":17102.62281168,"timestamp":1781788669395,"change":0.0224,"changeRate":0.023639,"amplitude":0.07366},"postHourTrading":{"tag":"盘后","latestPrice":0.955,"preClose":0.9674,"latestTime":"19:55 EDT","volume":15901,"amount":15344.1072,"timestamp":1781826957393,"change":-0.0124,"changeRate":-0.012818,"amplitude":0.02946},"volumeRatio":1.2426654420117944,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA","defaultTab":"news","newsList":[{"id":"2644089135","title":"BioCardia issues letter to shareholders on 2026 priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2644089135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644089135?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:24","pubTimestamp":1781789097,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) announced that the Company’s Chief Executive Officer, Peter Altman, issued the following letter to shareholders. “Upon completion ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocardia-issues-letter-to-shareholders-on-2026-priorities-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocardia-issues-letter-to-shareholders-on-2026-priorities-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085980","title":"BioCardia Outlines 2026 CardiAMP Strategy and Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085980?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:40","pubTimestamp":1781786429,"startTime":"0","endTime":"0","summary":"The latest update is out from BioCardia ( ($BCDA) ). On June 18, 2026, BioCardia issued a shareholder letter outlining its 2026 strategic prioritie...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-outlines-2026-cardiamp-strategy-and-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-outlines-2026-cardiamp-strategy-and-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083641","title":"BioCardia targets Q4 2026 Japan PMDA filing for CardiAMP cell therapy approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083641?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:04","pubTimestamp":1781784277,"startTime":"0","endTime":"0","summary":"BioCardia set a Q4 2026 goal for a Shonin submission to Japan’s PMDA for CardiAMP cell therapy in ischemic HFrEF.Planning initial Japan commercialization around a 20,000-patient subgroup of an estimated 300,000 ischemic heart-failure population.Targeting U.S. enrollment acceleration for the CardiAMP HF II confirmatory trial, positioned for potential FDA Premarket Approval support.Seeking partnerships to expand Helix and Heart3D as a delivery platform for cardiac gene and cell therapies, citing eight active discussions.Advancing licensing options for an allogeneic MSC platform with two FDA INDs, positioned for cardiac and pulmonary indications.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1QQBhw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","BCDA","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083307","title":"BioCardia publishes 2026 shareholder letter outlining priorities, strategic opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083307?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:02","pubTimestamp":1781784168,"startTime":"0","endTime":"0","summary":"BioCardia outlined 2026 priorities in a shareholder letter, led by a planned Japan PMDA Shonin submission for CardiAMP Cell Therapy in Q4 2026.Japan launch opportunity framed around about 300,000 ischemic heart failure patients, with initial approval expected to target about 20,000.Letter cited prior Japan reimbursement of USD 124,000 per procedure for chronic ischemic heart failure cell therapies.US focus remains enrollment of the confirmatory CardiAMP HF II trial, which FDA has indicated may support Premarket Approval.Strategy also targets partnering for Helix/Heart3D cardiac delivery platform, with eight early-stage gene or cell therapy discussions cited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the or","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL7q4fDN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644008338","title":"BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2644008338","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644008338?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:00","pubTimestamp":1781784001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUA3GFR9P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260029","title":"BioCardia wins Nasdaq extension to Oct. 7 to meet $2.5 million equity rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642260029?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:02","pubTimestamp":1781265736,"startTime":"0","endTime":"0","summary":"BioCardia received a Nasdaq notice that stockholders’ equity fell below the USD 2.5 million minimum under Listing Rule 5550.Nasdaq granted an extension to Oct. 7, 2026 to regain compliance following submission of a plan on May 25, 2026.BioCardia raised USD 4.9 million net via an at-the-market sale of 4,004,330 shares at an average USD 1.27 from April 1 to June 5, 2026.BioCardia believes stockholders’ equity now exceeds USD 2.5 million; Nasdaq will monitor compliance at the next periodic report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL2FRYCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642541882","title":"BioCardia CEO Peter Altman acquires 5,000 common shares valued at $4,250","url":"https://stock-news.laohu8.com/highlight/detail?id=2642541882","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642541882?lang=en_us&edition=fundamental","pubTime":"2026-06-10 05:37","pubTimestamp":1781041074,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman bought 5,000 common shares at USD 0.85.Altman’s direct holding rose to 298,266 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL9sWShN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman acquires 5,000 common shares valued at $4,250","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642461030","title":"BioCardia Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2642461030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642461030?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:44","pubTimestamp":1781001840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 06:44 ET (10:44 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148419","title":"BioCardia Raises $4.4 Million to Extend Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148419","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641148419?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:38","pubTimestamp":1780922306,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) has shared an update. On June 8, 2026, BioCardia announced it had raised approximately $4.4 million by selling 3,509,604 shar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-raises-4-4-million-to-extend-cash-runway?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-raises-4-4-million-to-extend-cash-runway?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641481986","title":"BioCardia - Net Proceeds Expected to Extend Cash Runway Into Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2641481986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641481986?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:00","pubTimestamp":1780920003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA6TBC6C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641481698","title":"Press Release: BioCardia Announces $4.4 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641481698","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641481698?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:00","pubTimestamp":1780920000,"startTime":"0","endTime":"0","summary":"Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales.SUNNYVALE, Calif., June 08, 2026  -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. No warrants were issued in this capital raise.BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP  autologous and CardiALLO allogeneic cell therapies are the Company's biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","BK4232","BK4022","BCDA","BK4555","BK4099","TM","BK4585","03160","BK4139","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641614762","title":"Sector Update: Healthcare Stocks Higher Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2641614762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641614762?lang=en_us&edition=fundamental","pubTime":"2026-06-06 03:49","pubTimestamp":1780688942,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF  adding 0.7%.The iShares Biotechnology ETF  declined 1.6%.In corporate news, Haemonetics  updated its financial reporting structure and will transition to two segments from three starting in Q1 fiscal 2027. The stock rose 1.8%.BioCardia  received confirmation from the US Food and Drug Administration that its ongoing trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed 23%.CareCloud  said shareholders approved all proposals put forward at the annual investor meeting on Thursday, including the re-election of Mahmud Haq and Cameron Munter to the board. CareCloud shares fell 1.5%.Vivos Therapeutics  entered a deal with its senior secured lender, Streeterville Capital, to exchange up to $4.5 million of its outstanding debt f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4167","BK4196","BCDA","IE00B19Z6F94.USD","IE0034390439.USD","LU0106261612.USD","BK4198","IE00B64QTZ34.USD","LU0205194284.USD","LABU","HAE","BK4139","BK4137","LU0128526141.USD","LU0029874061.USD","LU0012050646.USD","LU1169590202.USD","XLV","IE00BLDYK493.USD","BK4581","CCLD","LU0205193047.USD","HCSG","XBI","BK4585","LU1169589451.USD","IBB","VVOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641144689","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2641144689","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641144689?lang=en_us&edition=fundamental","pubTime":"2026-06-06 01:29","pubTimestamp":1780680543,"startTime":"0","endTime":"0","summary":"Solidion Technology  patented a lithium anode protection technology that paves the way for full-scale commercialization of lithium-sulfur, lithium-air, and anodeless lithium metal batteries, it said early Friday.Shares jumped 31% amid a surge in intraday trading volume to over 29.9 million from a daily average of roughly 68,000.Concrete Pumping  reported fiscal Q2 earnings and revenue above market expectations, and raised its full-year fiscal 2026 sales forecast, according to its earnings statement late Thursday.Shares climbed 31% following an increase in intraday trading volume to about 3.7 million from a daily average of 133,000.BioCardia  received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction, the company said.Shares advanced 26% as intraday trading volume catapulted to over 138.6 million from a d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCDA","PLS.AU","BK7095","BK4129","BK7507","GAB.SI","BK4096","ES3.SI","G3B.SI","STI","BBCP","BK4139","BK7504","STI.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641490561","title":"BUZZ-U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia","url":"https://stock-news.laohu8.com/highlight/detail?id=2641490561","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641490561?lang=en_us&edition=fundamental","pubTime":"2026-06-05 23:58","pubTimestamp":1780675103,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardiaWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning New","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nL6N42D0UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","BK4202","BCDA","GIII","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641114894","title":"BioCardia Gains FDA Path for CardiAMP PMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2641114894","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641114894?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:34","pubTimestamp":1780662858,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) has issued an update. On June 5, 2026, BioCardia announced that minutes from its Q-Sub meeting with the FDA’s Center for Biol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-gains-fda-path-for-cardiamp-pma-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-gains-fda-path-for-cardiamp-pma-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BCDA","BK4139","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641110779","title":"FDA confirms CardiAMP Heart Failure II Trial may support premarket approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2641110779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641110779?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:10","pubTimestamp":1780661444,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research, or CBER, on the Car...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-confirms-cardiamp-heart-failure-ii-trial-may-support-premarket-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-confirms-cardiamp-heart-failure-ii-trial-may-support-premarket-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BCDA","LABU","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641711065","title":"BioCardia says FDA confirms CardiAMP HF II trial may support PMA for CardiAMP cell therapy in ischemic HFrEF","url":"https://stock-news.laohu8.com/highlight/detail?id=2641711065","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641711065?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:02","pubTimestamp":1780660929,"startTime":"0","endTime":"0","summary":"BioCardia received FDA meeting minutes indicating its ongoing CardiAMP Heart Failure II trial may support a PMA filing for CardiAMP in ischemic HFrEF.FDA feedback points to completed CardiAMP HF clinical data as supportive evidence, with additional trial evidence still needed to underpin a marketing application.No new trial results were presented in the announcement; the key update was a regulatory pathway signal that could accelerate commercialization planning.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL3DbXv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210150020.SGD","BCDA","IE00BN0W2W23.USD","BK4139","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4112","NDAQ","SG9999014021.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","IE00BN0W2V16.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641105871","title":"FDA Confirms Cardiamp HF Ii May Support Premarket Approval of Cardiamp Cell Therapy for Ischemic Hfref","url":"https://stock-news.laohu8.com/highlight/detail?id=2641105871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641105871?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:00","pubTimestamp":1780660800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUA8MBM20:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698127","title":"BioCardia says Japan PMDA advice clears path for CardiAMP approval filing in ischemic heart failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698127","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698127?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:04","pubTimestamp":1779969898,"startTime":"0","endTime":"0","summary":"BioCardia received a Japan PMDA consultation record supporting a regulatory submission to seek approval for CardiAMP cell therapy in ischemic HFrEF.PMDA aligned on remaining submission items, including proof patients were on guideline-directed therapy, not eligible for revascularization, and more detail on major outcomes.The company set a seven-month timeline for its PMDA filing, targeting an initial eligible pool of about 20,000 patients in Japan.PMDA flagged post-marketing study expectations tied to patient selection, clinical decision-making, and specialist infrastructure, with MHLW issuing the commercialization certificate.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL8w1yTF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","BCDA","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698693","title":"BioCardia Announces Japan Pmda Record of Advice Supports Regulatory Submission for Approval of Cardiamp Cell Therapy for Ischemic Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698693?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA4V9W7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":0.2167},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.1938},{"period":"6month","weight":-0.2383},{"period":"1year","weight":-0.5437},{"period":"ytd","weight":-0.2261}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066663},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017269},{"month":3,"riseRate":0.25,"avgChangeRate":-0.022375},{"month":4,"riseRate":0.375,"avgChangeRate":0.007226},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09523},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.038345},{"month":7,"riseRate":0.5,"avgChangeRate":-0.016411},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102769},{"month":9,"riseRate":0.375,"avgChangeRate":0.008782},{"month":10,"riseRate":0.375,"avgChangeRate":-0.049332},{"month":11,"riseRate":0.5,"avgChangeRate":0.042585},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}